Status:
COMPLETED
Sorafenib Chemoembolization Evaluation Controlled Trial
Lead Sponsor:
Air Force Military Medical University, China
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This prospective, multicenter, randomized, controlled study aims to evaluate the efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) in advanced hepatocellular carcin...
Detailed Description
PRIMARY OBJECTIVE: To compare the overall survival of selected advanced HCC patients treated with sorafenib combined with TACE with sorafenib alone. SECONDARY OBJECTIVES: 1. To compare the time to ...
Eligibility Criteria
Inclusion
- Prior informed consent
- Advanced stage HCC/ Barcelona Clinic Liver Cancer(BCLC) C stage
- Confirmed Diagnosis of HCC:
- Cirrhotic subjects: Clinical diagnosis by Asian Pacific Association for the Study of the Liver(AASLD) criteria.
- Non-cirrhotic subjects: for subjects without cirrhosis, histological or cytological confirmation is mandatory
- Documentation of original biopsy for diagnosis is acceptable
- Child Pugh class A without ascites or hepatic encephalopathy
- Eastern Cooperative Oncology Group(ECOG) Performance Status of 0-1
- At least one uni-dimensional lesion measurable by CT-scan or MRI according to the RECIST, mRECIST and EASL criteria,respectively
- single lesion\>5cm
- 2-3 lesions, at least one lesion\>3cm if more than 4 lesions, no limitation of the tumor size, but the sum of size of all tumor lesions should be less than 50% of liver parenchyma.
- Male or female subjects ≥ 18 years of age
- Ability to swallow oral medications
- Life expectancy of at least 12 weeks
- Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 4 weeks after the completion of trial
- Adequate bone marrow, liver and renal function as assessed by central lab by means of the following laboratory requirements from samples within 7 days prior to randomization:
- Hemoglobin \> 9.0 g/dl
- Absolute neutrophil count (ANC) \>1,500/mm3
- Platelet count≥50x109/L
- ALB≥28g/L
- Total bilirubin \< 2 mg/dL
- Alanine aminotransferase(ALT) and aspartate aminotransferase(AST) \< 5 x upper limit of normal
- Blood urea nitrogen(BUN) and creatinine \< 1.5 x upper limit of normal
- International normalized ratio(INR) \< 1.7, or prothrombin time（PT） \< 4 seconds above control
Exclusion
- Diffuse HCC or tumor burden ≥50% of liver parenchyma
- Main portal vein obstruction, vascular invasion in hepatic vein or inferior vena cava
- Presence of metastasis in biliary tract,brain or bone
- Poor blood supply for the liver tumor lesions; poor blood supply refers that the tumor lesions fail to show obvious contrast uptake in the arterial phase and washout in venous or late phases by CT scan or MRI
- Any contraindications for hepatic embolization procedures:
- Known hepatofugal blood flow
- Known porto-systemic shunt
- Renal failure / insufficiency requiring hemo-or peritoneal dialysis
- Target lesions having previously been treated with local therapy such as resection of HCC, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI)
- Other molecular target drugs ongoing or completed \< 4 weeks prior to the baseline scan
- Prior transarterial embolization or systemic chemotherapy
- Any ≥ CTC adverse events(AEs) grade 2 acute toxic effects of any prior local treatment
- Patients with untreated varices or active bleeding
- History of cardiac disease:
- Congestive heart failure \>New York Heart Association (NYHA) class 2
- Uncontrolled hypertension
- Known history of HIV infection
- Active clinically serious infections (\> grade 2 NCI-CTCAE Version 3.0), except for Hepatitis B virus(HBV) and hepatitis C virus(HCV) infection
- Clinically significant gastrointestinal bleeding within 4 weeks prior to start of study drug
- Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months prior to the first dose of study drug
- Previous or concurrent cancer that is distinct in primary site or histology from HCC. Any cancer curatively treated \>3 years prior to entry is permitted
- Any contraindication for sorafenib or doxorubicin administration
- Pregnant or breast-feeding subjects
- Any disease(within 6 months of randomization)which could affect the evaluation of the study drug
- Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study
- Major surgery within 4 weeks prior to start of study drug (e.g. thoracolaparotomy is not allowed, but noninvasive surgery, e.g. biopsy, is allowed)
- Autologous bone marrow transplant or stem cell rescue within 1 year prior to start of study drug
- History of organ allograft
Key Trial Info
Start Date :
September 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT01906216
Start Date
September 1 2013
End Date
June 30 2022
Last Update
August 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital of Digestive Disease
Xi'an, Shaanxi, China, 710032